The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | Poziotinib in pretretaed, HER2 exon 20 insertion NSCLC
Xiuning Le, MD PhD, The University of Texas MD Anderson Cancer Centre, Houston, TX, outlines the outcomes of a Phase II study (NCT03318939) of poziotinib, a tyrosine kinase inhibitor (TKI), in HER2 exon 20 insertion non-small cell lung cancer (NSCLC). The study evaluated the efficacy of poziotinib in patients who progressed after chemotherapy and trastuzumab deruxtecan, an FDA-approved antibody-drug conjugate (ADC) for patients with HER2+ NSCLC. The trial enrolled eligible patients from the ZENITH20 trial (NCT03318939) who had received two lines of therapy. Results demonstrated a preserved progression-free survival, tumour response and safety. Dr Le suggests the report will be useful in strategizing for patients who progressed after chemotherapy, and the study confirms the hypothesis that small molecular therapy preserves the same efficacy after ADC therapy. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
